Clyburn Frank 4

What Happened Frank Clyburn, a director of Kailera Therapeutics, was awarded a derivative grant covering 38,300 shares on April 16, 2026. The Form 4 reports the acquisition price as $0.00 (derivative). This is a compensation award (not an open-market purchase or sale).

Key Details

• Transaction date: April 16, 2026; Form 4 filed April 20, 2026 (within the normal two-business-day filing window).
• Amount: 38,300 shares reported as a derivative award at $0.00 per share.
• Post-transaction holdings: Not specified in the filing.
• Footnote: The award is described as options that "vest and become exercisable as to 100% of the underlying shares on April 16, 2027," subject to continued service.
• No sale, purchase for cash, or immediate disposition was reported.

Context This filing documents a time-based equity award (options) that vests in one year; it represents compensation rather than a market signal like an open-market buy or sell. There is no indication in the filing of a cashless exercise or sale of shares at this time.